Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor, L. Robert, B. Chmielowski, M. Spasić, G. Henry, V. Ciobanu, Alisha West, M. Carmona, C. Kivork, E. Seja, Grace Cherry, Antonio Gutierrez, T. Grogan, C. Mateus, G. Tomasic, J. Glaspy, R. Emerson, H. Robins, R. Pierce, D. Elashoff, C. Robert, A. Ribas (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 515
K. Hall, K. Scott, A. Rose, M. Desborough, K. Harrington, H. Pandha, C. Parrish, R. Vile, M. Coffey, D. Bowen, F. Errington-Mais, A. Melcher (2012)
Reovirus-Mediated Cytotoxicity and Enhancement of Innate Immune Responses Against Acute Myeloid LeukemiaBioResearch Open Access, 1
E. Maloney, O. Morgan, B. Widner, E. Werner, D. Fuchs (2000)
Central nervous system activation of the indoleamine-2,3-dioxygenase pathway in human T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.The Journal of infectious diseases, 181 6
M. McLemore, M. Haigentz, Richard Smith, G. Nuovo, L. Alós, A. Cardesa, M. Brandwein-Gensler (2010)
Head and Neck Squamous Cell Carcinomas in HIV-Positive Patients: A Preliminary Investigation of Viral AssociationsHead and Neck Pathology, 4
Christian Grossardt, Christine Engeland, S. Bossow, N. Halama, K. Zaoui, M. Leber, C. Springfeld, D. Jaeger, C. Kalle, G. Ungerechts (2013)
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.Human gene therapy, 24 7
H. Ikeda, L. Old, R. Schreiber (2002)
The roles of IFNγ in protection against tumor development and cancer immunoeditingCytokine & Growth Factor Reviews, 13
Roy Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid, M. Gordon, Jeffery Sosman, David McDermott, J. Powderly, S. Gettinger, H. Kohrt, L. Horn, Donald Lawrence, S. Rost, M. Leabman, Yuanyuan Xiao, A. Mokatrin, H. Koeppen, P. Hegde, I. Mellman, Daniel Chen, F. Hodi (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 515
Raghava Potula, L. Poluektova, Bryan Knipe, Jesse Chrastil, D. Heilman, H. Dou, O. Takikawa, D. Munn, H. Gendelman, Y. Persidsky (2005)
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.Blood, 106 7
F. Goshima, S. Esaki, C. Luo, M. Kamakura, H. Kimura, Y. Nishiyama (2014)
Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte–macrophage colony‐stimulating factor for murine ovarian cancerInternational Journal of Cancer, 134
L. Steele, F. Errington, R. Prestwich, E. Ilett, K. Harrington, H. Pandha, M. Coffey, P. Selby, R. Vile, A. Melcher (2011)
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingMolecular Cancer, 10
Wan-li Liu, Yue-hao Lin, Han Xiao, Shan Xing, Hao Chen, P. Chi, Ge Zhang (2014)
Epstein-Barr Virus Infection Induces Indoleamine 2,3-Dioxygenase Expression in Human Monocyte-Derived Macrophages through p38/Mitogen-Activated Protein Kinase and NF-κB Pathways: Impairment in T Cell FunctionsJournal of Virology, 88
Toshio Watanabe, Antonio Bertoletti, Antonio Bertoletti, T. Tanoto, T. Tanoto (2010)
PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infectionJournal of Viral Hepatitis, 17
T. Kottke, Jill Thompson, R. Díaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, R. Vile (2009)
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2Clinical Cancer Research, 15
Weiwei Shen, M. Patnaik, Autumn Ruiz, S. Russell, K. Peng (2016)
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Blood, 127 11
R. Prestwich, E. Ilett, F. Errington, R. Díaz, L. Steele, T. Kottke, Jill Thompson, Feorillo Galivo, K. Harrington, H. Pandha, P. Selby, R. Vile, A. Melcher (2009)
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and ReplicationClinical Cancer Research, 15
Mezache (2016)
Modulation of PD-L1 and CD8 activity in idiopathic and infectious chronic inflammatory conditionsAppl Immun Mol Morph
K. Edelmann, Christopher Wilson (2001)
Role of CD28/CD80-86 and CD40/CD154 Costimulatory Interactions in Host Defense to Primary Herpes Simplex Virus InfectionJournal of Virology, 75
Louisa Mezache, B. Paniccia, Angelique Nyinawabera, G. Nuovo (2015)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancersModern Pathology, 28
P. Ott, F. Hodi (2012)
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.Chinese clinical oncology, 2 1
M. El-Far, P. Ancuța, J. Routy, Yuwei Zhang, Wendy Bakeman, Rebeka Bordi, S. DaFonseca, E. Said, A. Gosselin, Tévy-Suzy Tep, Q. Eichbaum, J. Grevenynghe, O. Schwartz, G. Freeman, E. Haddad, N. Chomont, R. Sékaly (2015)
Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation.The Journal of general virology, 96 Pt 6
R. Adair, K. Scott, S. Fraser, F. Errington-Mais, H. Pandha, M. Coffey, P. Selby, G. Cook, R. Vile, K. Harrington, G. Toogood, A. Melcher (2013)
Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cellsInternational Journal of Cancer, 132
K. Peng, C. Teneyck, E. Galanis, K. Kalli, L. Hartmann, S. Russell (2002)
Intraperitoneal therapy of ovarian cancer using an engineered measles virus.Cancer research, 62 16
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.The New England journal of medicine, 366 26
O. Adams, K. Besken, C. Oberdörfer, C. Mackenzie, D. Rüssing, W. Däubener (2004)
Inhibition of human herpes simplex virus type 2 by interferon γ and tumor necrosis factor α is mediated by indoleamine 2,3-dioxygenaseMicrobes and Infection, 6
J. Zager, K. Delman, S. Malhotra, M. Ebright, J. Bennett, Tara Kates, Mark Halterman, H. Federoff, Y. Fong (2001)
Combination Vascular Delivery of Herpes Simplex Oncolytic Viruses and Amplicon Mediated Cytokine Gene Transfer Is Effective Therapy for Experimental Liver CancerMolecular Medicine, 7
H. Watanabe, F. Wells, M. Major (2010)
Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phaseJournal of Viral Hepatitis, 17
Anna Schurich, P. Khanna, A. Lopes, Ki Han, D. Peppa, L. Micco, G. Nebbia, P. Kennedy, A. Geretti, G. Dusheiko, M. Maini (2011)
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infectionHepatology, 53
N. Gupta, P. Hegde, M. Lecerf, Minu Nain, Manpreet Kaur, Manjula Kalia, S. Vrati, J. Bayry, S. Lacroix-Desmazes, S. Kaveri (2014)
Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD‐L1 on dendritic cellsEuropean Journal of Immunology, 44
G. Nuovo, M. Garofalo, N. Valeri, V. Roulstone, S. Volinia, D. Cohn, M. Phelps, K. Harrington, R. Vile, A. Melcher, E. Galanis, Sarah Sehl, R. Adair, K. Scott, A. Rose, G. Toogood, M. Coffey (2012)
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesModern Pathology, 25
F. Bai, Yin Yu, H. Tian, G. Ren, Hui Wang, Bing-xi Zhou, Xiao-hui Han, Qing-Zhong Yu, Deshan Li (2014)
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapyCancer Biology & Therapy, 15
Therapy with checkpoint inhibitors represents a major advance in cancer treatment. The purpose of this study was to examine the expression patterns of the checkpoint proteins programmed death ligand 1 (PD L1), PD L2, indoleamine 2,3-dioxygenase 1 (IDO1), and cytotoxic T-lymphocyte antigen 4 (CTLA4) in cancers including those associated with viral infections. Normal, noninflamed tissues rarely express checkpoint proteins with exceptions including the placenta and stomach. Expression of PD L1 was noted in 30%, PD L2 in 18%, IDO1 in 13%, and CTLA4 in 14% of 333 nonviral malignancies including endometrial, ovarian, lung, and breast cancers. The expression of each checkpoint protein was significantly higher among 166 cases of viral-related (mostly human papillomavirus) cancers where expression of PD L1 was noted in 84%, PD L2 in 67%, IDO1 in 61%, and CTLA4 in 37% (each P value <0.001); 97% of the viral-related cancers showed expression of at least 1 checkpoint protein. In addition, over 90% of the CD8+ cells in the viral-associated cancers were quiescent based on low coexpression of Ki-67 as well as pSTAT1. It is concluded that viral infection in cancers is associated with the increased expression of key checkpoint proteins. This indicates that cancers with productive viral infection may be better targets for checkpoint inhibitor therapy.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jul 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.